Entry into Force and Transition under Moroccan Law 84-12

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Loi n° 84-12 did not become fully effective upon publication. Article 50 states expressly that the law enters into force on the date of entry into force of the regulatory texts adopted for its implementation, that those texts must be published in the Bulletin officiel within one year of the publication of the law, and that during the transition period the pre-existing registration procedures continue to apply. The same article adds a frequently overlooked operational duty: manufacturers, importers, exporters and distributors must carry out a complete inventory of the devices in their stock during the transition period and place it at the disposal of the competent authority. The timeline that resulted from this mechanism is concrete: the law was published on August 30, 2013, the implementing decree followed on September 18, 2014, and the ministerial orders arrived in 2015. In other words, the law itself announced a delay of roughly two years between publication and full operation, and every compliance deadline in this framework should be read through Article 50 before being treated as live.

2. Legal basis

The entry-into-force mechanism spans three instruments: the article of the law that defines the conditional mechanism and the repeal rule, and the two subsidiary texts whose publication actually switched the regime on.

InstrumentReferencePublication dateProvisions
Medical Devices Law (Loi n° 84-12)Dahir n° 1-13-90August 30, 2013 (Bulletin officiel n° 6188, September 19, 2013)Article 50 (entry into force and transition); Article 51 (repeal)
Implementing decree of Law 84-12 (Décret n° 2-14-607)Décret n° 2-14-607September 18, 2014Subsidiary text triggering entry into force
Ministerial order on registration and placing on the marketArrêté n° 2855-15August 4, 2015Subsidiary text triggering entry into force

3. Expert insights

Insight 1: This is conditional entry into force as a drafting choice. The Moroccan legislator handed the switch of the new law to its subsidiary texts. The benefit is that no obligation becomes enforceable before the instruments needed to comply with it exist; the cost is that companies must actively track subsidiary texts to know when duties begin. GRZAN describes provisions of this kind as dormant clauses: the text exists, but it waits to be activated. The practical discipline that follows is simple but strict — for every obligation traced to an enabling article of the law, the compliance calendar is built from the publication of the corresponding decree or ministerial order, never from the date of the parent law itself.

Insight 2: The stock inventory duty in Article 50 is the clause most often missed. The provision requires manufacturers, importers, exporters and distributors to complete a full inventory of the devices they hold during the transition period and to place it at the disposal of the competent authority. For companies that had already distributed devices in Morocco before the new regime took effect, this is a one-time compliance action, and its retained proof is also the documentary basis for demonstrating later that the installed base was lawful at the transition. Companies that skip the inventory cannot retroactively rebuild that evidence chain when the authority or a customer asks for it.

Insight 3: The transition period is not a grace period. Article 50, second paragraph, preserves the application of the former registration procedures, but item 17 of Article 1 simultaneously prohibits healthcare institutions from acquiring unregistered devices from the date the law was published in the Bulletin officiel. The two provisions operate in parallel and point in different directions: on the sales side there is transition space, while on the procurement side the constraint bites from the publication date. A distributor who reads the transition period as free time to keep selling unregistered stock into hospitals has misread the clock that matters for its customers.

Insight 4: The repeal in Article 51 is a partial repeal. Article 51 provides that Chapter III of Book I of Loi n° 17-04 is repealed as of the date on which the provisions of the present law concerning device registration take effect. The repeal is confined to that chapter; the remaining parts of Loi n° 17-04, including the pharmacy monopoly and the duties of pharmacists, continue in force. Internal regulatory maps should record the boundary precisely, because citing a repealed provision and overlooking a surviving one are equally common consequences of treating the repeal as wholesale.

4. Practical recommendations

  1. Date every obligation from the subsidiary text. For any provision of the law that delegates its content (registration, second-hand devices, traceability), first confirm that the corresponding decree or ministerial order has been published in the Bulletin officiel before treating the duty as enforceable.
  2. Document the existing stock once, properly. If the company already has devices placed in Morocco, produce the inventory required by Article 50 and keep the proof of submission as the evidence chain for the lawful installed base.
  3. Run two different clocks for sales and procurement. For tenders and supply to healthcare institutions, apply the earlier constraint of item 17 of Article 1 rather than the transition-period timeline.
  4. Record the repeal boundary in the internal regulatory map. State expressly that Chapter III of Book I of Loi n° 17-04 is repealed and that the rest remains applicable, so that drafting and citations stay on the right side of the line.

5. Verification checklist

  • □ The conditional entry-into-force mechanism of Article 50 has been confirmed
  • □ Publication of the subsidiary texts (Décret n° 2-14-607 and Arrêté n° 2855-15 and its companions) has been confirmed
  • □ The stock inventory of existing devices has been completed and the proof of submission archived
  • □ The transition timeline for the sales side has been distinguished from the procurement-side constraint date
  • □ The internal regulatory map marks Chapter III of Book I of Loi n° 17-04 as repealed
  • □ The company’s own role (manufacturer, importer, exporter or distributor) under the inventory duty has been identified
  • □ The scope of the stock inventory covers all devices located within Morocco

Regulatory information verified as of October 30, 2026. GRZAN assists companies with entry-into-force analysis, transition compliance, stock inventory documentation and registration projects before AMMPS in Morocco. For project inquiries, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail